RESUMO
Based on the structure of R115777 (tipifarnib, Zarnestra), a series of farnesyltransferase inhibitors have been synthesized by modification of the 2-quinolinone motif and transposition of the 4-chlorophenyl ring to the imidazole or its replacement by 5-membered rings. This has yielded a novel series of potent farnesyltransferase inhibitors.
Assuntos
Antineoplásicos/farmacologia , Inibidores Enzimáticos/farmacologia , Farnesiltranstransferase/antagonistas & inibidores , Quinolonas/farmacologia , Antineoplásicos/química , Inibidores Enzimáticos/química , Espectroscopia de Ressonância Magnética , Modelos Moleculares , Estrutura Molecular , Quinolonas/químicaRESUMO
We describe the discovery and the structure-activity relationship of a new series of quinoline derivatives acting as selective and highly potent noncompetitive mGlu1 antagonists. We first identified cis-10 as a fairly potent mGlu1 antagonist (IC(50) = 20 nM) in a cell-based signal transduction assay on the rat mGlu1 receptor expressed in CHO-K1 cells, and then we were able to design and synthesize highly potent compounds on both rat and human mGlu1 receptors as exemplified by compound cis-64a, which has an antagonist potency of 0.5 nM for the human mGlu1 receptor. We briefly present and discuss the in vitro metabolic stability of the compounds in human liver microsomes. We finally report the pharmacokinetic properties of our lead compound cis-64a.
Assuntos
Quinolinas/síntese química , Receptores de Glutamato Metabotrópico/antagonistas & inibidores , Animais , Disponibilidade Biológica , Células CHO , Cálcio/metabolismo , Linhagem Celular Tumoral , Cricetinae , Cricetulus , Meia-Vida , Humanos , Técnicas In Vitro , Líquido Intracelular/metabolismo , Microssomos Hepáticos/metabolismo , Quinolinas/farmacocinética , Quinolinas/farmacologia , Ratos , Receptores de Glutamato Metabotrópico/fisiologia , Transdução de Sinais/efeitos dos fármacos , Estereoisomerismo , Relação Estrutura-AtividadeRESUMO
R115777 (R)-6-amino[(4-chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone is a potent and selective inhibitor of farnesyl protein transferase with significant antitumor effects in vivo subsequent to oral administration in mice. Taking its roots into Janssen's ketoconazole and retinoic acid catabolism programs, our interest into Ras prenylation process led us stepwise to identify the key structural features of R115777. Methodology, structure activity relationships, and pharmacology will be presented. R115777 is currently in phase III clinical evaluation.
Assuntos
Alquil e Aril Transferases/antagonistas & inibidores , Antineoplásicos/química , Inibidores Enzimáticos/química , Quinolonas/química , Animais , Antineoplásicos/farmacologia , Ensaios Clínicos como Assunto , Inibidores Enzimáticos/farmacologia , Humanos , Camundongos , Estrutura Molecular , Neoplasias/tratamento farmacológico , Prenilação de Proteína/efeitos dos fármacos , Quinolonas/farmacologia , Relação Estrutura-AtividadeRESUMO
The evaluation of structure-activity relationships associated with the modification of the R115777 quinolinone ring moiety displaying potent in vitro inhibiting activity is described.
Assuntos
Alquil e Aril Transferases/antagonistas & inibidores , Antineoplásicos/síntese química , Azepinas/síntese química , Quinazolinas/química , Quinolonas/química , Animais , Antineoplásicos/farmacologia , Azepinas/química , Azepinas/farmacologia , Farnesiltranstransferase , Humanos , Técnicas In Vitro , Indicadores e Reagentes , Camundongos , Microssomos Hepáticos/efeitos dos fármacos , Microssomos Hepáticos/metabolismo , Quinazolinas/síntese química , Quinazolinas/farmacologia , Quinolonas/síntese química , Quinolonas/farmacologia , Relação Estrutura-Atividade , Ensaios Antitumorais Modelo de XenoenxertoRESUMO
Replacement of the 1-methylimidazol-5-yl moiety in the farnesyltransferase inhibitor ZARNESTRA series by a 4-methyl-1,2,4-triazol-3-yl group gave us compounds with similar structure-activity relationship profiles showing that this triazole is potentially a good surrogate to imidazole for farnesyltransferase inhibition.
Assuntos
Alquil e Aril Transferases/antagonistas & inibidores , Inibidores Enzimáticos/síntese química , Compostos Heterocíclicos/síntese química , Quinolonas/síntese química , Quinolonas/farmacologia , Triazóis/síntese química , Administração Oral , Animais , Antineoplásicos/síntese química , Antineoplásicos/farmacologia , Divisão Celular/efeitos dos fármacos , Inibidores Enzimáticos/administração & dosagem , Inibidores Enzimáticos/química , Inibidores Enzimáticos/farmacologia , Farnesiltranstransferase , Compostos Heterocíclicos/administração & dosagem , Compostos Heterocíclicos/química , Compostos Heterocíclicos/farmacologia , Humanos , Cinética , Camundongos , Microssomos Hepáticos/efeitos dos fármacos , Microssomos Hepáticos/metabolismo , Modelos Moleculares , Conformação Molecular , Quinolonas/administração & dosagem , Relação Estrutura-Atividade , Triazóis/química , Triazóis/farmacologiaRESUMO
A series of (4-chlorophenyl)-alpha-(1-methyl-1H-imidazol-5-yl)azoloquinolines and -quinazolines was prepared. These compounds displayed potent Farnesyl Protein Transferase inhibitory activity and tetrazolo[1,5-a]quinazolines are promising agents for oral in vivo inhibition.